Gina Mazzariello Sells 4,169 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Gina Mazzariello sold 4,169 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, February 24th. The stock was sold at an average price of $3.15, for a total value of $13,132.35. Following the transaction, the insider now owns 134,921 shares in the company, valued at approximately $425,001.15. This represents a 3.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Gina Mazzariello also recently made the following trade(s):

• On Monday, February 3rd, Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock. The stock was sold at an average price of $3.49, for a total value of $12,836.22.

Amylyx Pharmaceuticals Trading Up 3.8 %

AMLX traded up $0.12 on Friday, hitting $3.28. The company had a trading volume of 277,919 shares, compared to its average volume of 1,819,346. The firm has a market cap of $224.84 million, a P/E ratio of -0.86 and a beta of -0.54. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $19.42. The company's fifty day moving average price is $3.60 and its 200 day moving average price is $3.85.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Robert W. Baird upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and lifted their price target for the stock from $3.00 to $11.00 in a report on Monday, November 18th. HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a report on Thursday, December 5th. Finally, Baird R W upgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.33.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several institutional investors have recently bought and sold shares of AMLX. abrdn plc grew its position in Amylyx Pharmaceuticals by 1,567.9% in the 3rd quarter. abrdn plc now owns 1,972,242 shares of the company's stock valued at $6,390,000 after acquiring an additional 1,853,995 shares in the last quarter. Boxer Capital Management LLC acquired a new position in Amylyx Pharmaceuticals in the 4th quarter valued at about $6,615,000. Bank of America Corp DE grew its position in Amylyx Pharmaceuticals by 165.9% in the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company's stock valued at $9,171,000 after acquiring an additional 1,513,748 shares in the last quarter. Alpha Wave Global LP acquired a new position in Amylyx Pharmaceuticals in the 3rd quarter valued at about $2,169,000. Finally, Walleye Capital LLC grew its position in Amylyx Pharmaceuticals by 986.5% in the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company's stock valued at $2,173,000 after acquiring an additional 608,874 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.